Medication info

Piome Metformin 15/850 milligrams

Prescription medicationTabletExpired
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
White to grayish white film-coated oblong tablet
Packaging
30 tablets / PTP [(10 tablets/PTP) × 3]
Approval status
Expired

MFDS item code 201906479 · Approved 2019.09.17

This product's status changed to Expired on 2024.09.17. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
In the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, assess the adequacy of the treatment response, and adjust the dose gradually. 2. Patients switching from concomitant pioglitazone and metformin therapy: Patients switching from concomitant pioglitazone and metformin therapy to this medicine may start at their previous doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dosage adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose of this medicine increased to the maximum dose. After administering this medicine to a patient or increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended, provided that glycemic control measured by FPG has not worsened.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Insulin-dependent diabetes
  • blood sugar management disorders
  • type 2 diabetes
View approved original text

This drug aids in the management of blood sugar levels in patients with type 2 diabetes who are not dependent on insulin, as a supplement to dietary and exercise therapies. It is especially used when sufficient blood sugar control cannot be achieved through monotherapy with Metformin or Pioglitazone alone. Additionally, it can serve as a substitute for combination therapy of Pioglitazone and Metformin. Management of type 2 diabetes requires nutritional counseling, weight loss, and regular physical activity, and improving these lifestyle habits is crucial for enhancing the efficacy of drug therapy. Therefore, this medication is used to improve blood sugar control as part of this comprehensive treatment strategy.

Dosage and Administration

Adult dosage

In the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, assess the adequacy of the treatment response, and adjust the dose gradually. 2. Patients switching from concomitant pioglitazone and metformin therapy: Patients switching from concomitant pioglitazone and metformin therapy to this medicine may start at their previous doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dosage adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose of this medicine increased to the maximum dose. After administering this medicine to a patient or increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended, provided that glycemic control measured by FPG has not worsened.

Precautions

This drug helps regulate blood sugar. However, several important precautions must be strictly followed while taking this medication. First, this drug should not be administered to patients with impaired kidney function. If the kidneys cannot properly excrete the drug, it may accumulate in the body and pose risks. Moreover, this medication should not be used in patients with severe heart failure or active bladder cancer. For these patients, the drug may pose further health risks. This medication can cause a rare but very serious side effect known as lactic acidosis. Lactic acidosis is a condition characterized by an excessive buildup of lactic acid in the body, with symptoms including fatigue, muscle pain, difficulty breathing, and abdominal pain. If these symptoms occur, consult a physician immediately. If dehydration, hypoxia, or sepsis occurs during the use of this drug, administration should be stopped immediately. Patients with liver impairment should also refrain from using this drug, as a decreased ability of the liver to process medications can increase the risk of side effects. Alcohol can interact with this medication and affect lactic acid metabolism, potentially increasing risks, so excessive drinking should be avoided while taking this medication. This drug can worsen heart failure, so if symptoms of heart failure such as weight gain, shortness of breath, or edema occur, inform your doctor immediately. Additionally, this medication can cause weight gain and edema; thus, any changes should be discussed with healthcare professionals. Pregnant or breastfeeding women should not take this medication, and safety and efficacy have not been established for pediatric patients. Elderly individuals may have decreased kidney function, and therefore, the dosage of this medication should be carefully adjusted, and regular kidney function assessments should be conducted. While taking this medication, regular checks of blood sugar, blood tests, and kidney function tests should be performed to monitor health status closely. Finally, there may be interactions with other medications taken concurrently with this drug, so it is essential to consult a physician or pharmacist about any additional medications.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • weakness
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 37 more
  • upper respiratory infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower extremity edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • diabetic macular edema
  • hepatic failure
  • congestive heart failure
  • indigestion
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intragastric air retention
  • increased serum creatinine
  • increased blood urea
  • fracture
  • abnormal blood glucose
  • gastroenteritis
  • failure of blood glucose control
  • hypoglycemia
  • edema
  • urinary disorder
  • urgency

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish white film-coated oblong tablet

Package unit

30 tablets / PTP [(10 tablets/PTP) × 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.